Login to Your Account

Advancis Starting Another Trial, Selling Keflex Rights For $12M

By Jennifer Boggs

Friday, September 16, 2005
Advancis Pharmaceutical Corp. is giving Amoxicillin Pulsys another chance. After the product, which combines the antibiotic amoxicillin with the company's once-a-day controlled-release Pulsys technology, missed in two pivotal trials earlier this year - and prompted a staff reduction and a dropped partnership - Advancis has rebounded with plans for another Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription